Lexaria Bioscience (Lexaria Bioscience) 3-Year Revenue Growth Rate : -37.50% (As of Feb. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lexaria Bioscience 3-Year Revenue Growth Rate?

Lexaria Bioscience's Revenue per Share for the three months ended in Feb. 2024 was $0.00.

During the past 12 months, Lexaria Bioscience's average Revenue per Share Growth Rate was -20.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -37.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was -25.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Lexaria Bioscience was 155.30% per year. The lowest was -83.20% per year. And the median was -8.55% per year.

Competitive Comparison of Lexaria Bioscience's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Lexaria Bioscience's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's 3-Year Revenue Growth Rate falls into.

Lexaria Bioscience 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Lexaria Bioscience (NAS:LEXXW) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Lexaria Bioscience 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

LEXX:USA

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.